Abstract: Placental extracts contain various bioactive agents and are thought to be a prospective medicine for oral diseases. However, detailed information regarding their mechanisms with respect to treatment of periodontal diseases is not available, thereby hindering their reliable application in dentistry. In this study, we demonstrated that human placental extracts increased collagen type-1 production, which is linked to the regenerative capabilities of periodontal tissue, on primary human gingival fibroblasts in vitro. Generally, deterioration of periodontal tissue occurs when various types of cytokines are released by periodontal tissue cells in response to stimulation by plaque. However, we exhibited that human placental extracts hindered the pro-inflammatory cytokines such as interleukin (IL)-6 and IL-8 secretion from primary human gingival fibroblasts in vitro. The results contribute to understanding a therapeutic mechanism underlying the effect of human placenta extracts against periodontal disease by modulating the function of human gingival fibroblasts.
Introduction
Periodontal diseases linked to adult lifestyle-related diseases, are a biological response caused by complicated interactions between the host and mechanical stress or periodontal pathogens residing in the oral cavity [1] [2] [3] . Generally, deterioration of periodontal tissue occurs when various types of cytokines are released by periodontal tissue cells in response to stimulation by plaque 1) . In fact, inflamed periodontal tissue is known to exhibit elevated concentrations of cytokines such as interleukin (IL)-6 and IL-8 3) . IL-6 has a variety of functions, including the regulation of immune cell differentiation and multiplication 4) , stimulation of bone absorption, and exacerbation of periodontal disease 5) . IL-8 is believed to be involved in the stimulation of neutrophils and exacerbation of periodontal disease 6) .
Many cells, including macrophages or lymphocytes, are known to be intricately involved in the exacerbation of periodontal disease 1) . Human gingival fibroblasts (HGFs) are the most abundant cell type in gingival connective tissue and produce collagen while sustaining the structure or homeostasis of the periodontal tissue [7] [8] [9] . Placental extracts are produced by the purification of placenta through a process involving dialysis, heat treatment, and hydrolysis; they contain various biologically active substances such as amino acids, peptides, glycosaminoglycans, minerals, and growth factors 10) . Placental extracts are reported to exert effects that have medicinal value, such as the acceleration of anti-oxidative effects 11) , anti-inflammatory effects 11, 12) , wound healing 13) , and immune enhancement 14) . Therefore, placental extracts are processed by a variety of methods and are sold as drugs or quasidrugs. Even in the field of dentistry, there are many studies demonstrating the benefits of using placenta in periodontal diseases [15] [16] [17] [18] . However, these studies have focused entirely on clinical knowledge and therefore, it is unclear if the placenta has any effect on cellular function with respect to periodontal diseases. It is necessary to accumulate basic research data with cultured cells or with similar in vitro methods because of the complexity of the factors that cause periodontal disease, owing to the network of multiple cells and cytokines 19) increase collagen type-1 production and hinder pro-inflammatory cytokine secretion by HGFs 20) . To confirm this, we examined the effect of human placenta extracts on the production of type I collagen and inflammatory cytokines by HGFs in vitro. In addition, we attempted to clarify part of the mechanism underlying the action of human placenta extracts in periodontal diseases.
Materials and methods

Reagents
The following materials and antibodies were purchased:
Melsmon (human placenta extracts) was provided by Melsmon Pharmaceutical Co., Ltd. (Tokyo, Japan). Melsmon (2 ml) contains 100 mg of human placental hydrolysate. Lipopolysaccharide (LPS) from Porphyromonas gingivalis (P. gingivalis) (InvivoGen, Shatin, Hong Kong); anti-Interleukin (IL)-6, biotinylated anti-IL-6 antibodies (eBioscience, San Diego, USA); anti-IL-8 and biotinylated anti-IL-8 antibodies (R&D Systems, Shanghai, China); biotinylated anti-collagen type I antibody (Rockland,
Cell culture HGF cells were obtained according to the literature 21) . The HGFs were cultured in Dulbecco's Modified Eagle Medium (DMEM, Nissui Pharmaceutical Co., Ltd., Tokyo, Japan) with 10% fetal bovine serum (FBS), 100 units/ml penicillin G, and 100 g/ml streptomycin at 37ºC in an incubator with 5% CO 2 and 95% humidified air 22) . The HGFs used in this study were obtained from volunteers after obtaining appropriate informed consent. The Ethics Committee of Osaka Dental University approved the study (protocol 110778).
MTT assay
For MTT assay, the cells were cultured with Melsmon at 150 g/ml, 1500 g/ml, 15000 g/ml in DMEM containing 10% FBS (10% DMEM) for 24 h. The subsequent procedures were performed as described elsewhere 21) .
Enzyme-linked immunosorbent assays (ELISAs)
To assess cytokine production, HGFs (3.1  10 4 /cm 2 ) were cultured with mixtures of P. gingivalis LPS (100 ng/ml) and Melsmon (1500 g/ml) for 24 h. The culture media were then collected, and the cytokine levels were measured using the anti-IL-6 (1.0 g/ml) and biotinylated anti-IL-6 (0.6 g/ml), or anti-IL-8 (2.5 g/ml) and biotinylated anti-IL-8 (0.2 g/ml) antibodies.
To assess collagen production, HGFs (3.1  10 4 /cm 2 ) were cultured in DMEM containing 1% FBS with Melsmon at the same concentration mentioned above. The levels of collagen type I in the media were measured using the biotinylated anti-collagen type I antibody (0.2 g/ml). The ELISA procedure was performed as described in the user manual of the CytoSet kits (Biosource) 23) .
The cells used for assessing collagen production were lysed with 0.5% TritonX-100, and the protein concentration in the cell lysates were measured using a BCA protein assay kit (PIERCE). Collagen production was normalized to the protein content of the cell lysates.
Statistical analysis
Quantitative data were statistically analyzed using either oneway analysis of variance (ANOVA) followed by Dunnett's test, Student's t test or Tukey's test using the StatMate software (ATMS). Differences were considered to be significant at P < 0.05.
Results
We examined the effect of Melsmon on the viability of HGFs , and were exposed to media containing 150 g/ml, 1500 g/ml, 15000 g/ml Melsmon (left, center and right) for 24 h. All the data were compared with cells that were treated with control medium without Melsmon. Data are provided as mean ± S.D. (n = 3). *P < 0.05 and analyzed with ANOVA followed by a Tukey's test (vs. none). , and were exposed to media containing 1500 µg/ml Melsmon for 24 h. Data are provided as mean ± S.D. (n = 3). ***P < 0.001 analyzed with Student's t-test (vs. none).
using an MTT assay (Fig. 1) . Treatment with Melsmon significantly affect the viability of HGFs at concentrations of up to 1500 g/ml. The following experiments were conducted using 1500 g/ml of Melsmon.
We evaluated the effect of Melsmon on the production of type I collagen by HGFs, which is directly linked to the regenerative capabilities of periodontal tissue. In the cell viability evaluation, 1500 g/mL of Melsmon also enhanced production of type I collagen in HGFs by roughly 2.2 times compared with the control (Fig. 2 ). Fig. 3 shows the effect of Melsmon on the secretion of inflammatory cytokines by HGFs. IL-6 and IL-8 production from
HGFs was markedly accelerated in the presence of LPS stimulated P. gingivalis, a periodontal pathogenic bacterium that has a strong inflammation-inducing effect. On the other hand, the production of this cytokine in LPS stimulated P. gingivalis was significantly suppressed in the presence of Melsmon.
Discussion
Previous reports have shown that placental extracts contain growth factors such as transforming growth factor- (TGF-) 24, 25) . TGF- is known to improve the production of collagen in HGFs 26) .
In addition, Melsmon contains a variety of vitamins, which improve the production capabilities of collagen in HGFs 27) . When considering these points, we believe that the growth factors and vitamins in Melsmon can probably act to improve the collagen production by HGFs.
The results of this study show that Melsmon has a suppressive effect on LPS-induced production of cytokines by HGFs (Fig. 3) .
It has been reported that HGFs express the toll-like receptor (TLR)
genes TLR-1, -2, -3, -4, -5, and -9, which are widely known as receptors for pathogens, and that TLR-2, -3, -4, and -5 contribute to the expression of IL-8 28) . In addition, TLR-2 is known to be involved in IL-6 expression 29) . Placental cells secrete a variety of antimicrobial peptides and proteins (AMPs) such as bactericidal/ permeability-increasing protein (BPI), secretory leukocyte protease inhibitor (SLPI), human -defensin 2 (hBD2), and cathelicidin (CAP18) as a latent infection preventive barrier 30) . These proteins and peptides bind with LPS and work to suppress its binding function 31) . There is a possibility that these proteins and peptides might be present in the Melsmon used in this experiment. In this study, we also believe that AMPs are potentially involved in the Melsmon-mediated suppression of the LPSinduced inflammatory cytokine production 30, 31) . In this in vitro stu dy, we o bserved th at M el smo n simultaneously enhanced the production of type I collagen and suppressed the production of LPS-induced inflammatory cytokines (IL-6 and IL-8). These results indicate that the pharmacokinetic data from the powdered placenta extracts isolated from porcine tissue is similar to that of human aqueous placenta extracts in Melsmon 20) . In recent years, reports have questioned the value of animal testing due to the significant differences between animals and humans 32) . Even periodontal disease-related studies have not yielded models that recapitulate human periodontal disease 33) . With this background, the approach used here allows the acquisition of data regarding human periodontal diseases using gingival fibroblasts instead of animal testing. However, future studies using a reliable human periodontal disease model will be necessary to , and were exposed to media containing 1500 µg/ml Melsmon for 24 h. The IL-6 and IL-8 concentrations in the supernatant were measured by ELISA. Data are provided as mean ± S.D. (n = 3). ***P < 0.001, analyzed with ANOVA followed by a Tukey's test. The statistical differences among Melsmon (+/-) exposures with LPS administration are shown in the figure.
J.Hard Tissue Biology Vol. 25(3): 277-281, 2016 confirm the in vitro findings. In addition, periodontal diseaserelated inflammatory cytokines have not been studied comprehensively. In particular, there is a need for the comprehensive analyses of the effects of placental components on HGFs and the optimum concentration of placenta that has an effect on HGFs, in addition to a comparative investigation with various placental drugs. Nevertheless, we believe that the results of this study contribute to clarifying the clinical benefits of placenta.
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